Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Brain Tumors: early-phase trial registry

1 of 11 indexed Brain Tumors trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Brain Tumors: 11 US clinical trials tracked, 1 recruiting.

Brain Tumors is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Methodist Healthcare, running 1 of these trials.

Enrollment posture brief

Registry condition brain-tumors

OPEN 1 | RECR 9% | LATE 0 | EARLY 5 | RANK #1577 | SPON 1

Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%Brain Tumors (this)9%
Open-enrollment share among volume-matched conditions near Brain Tumors

Brain Tumors lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Brain Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Brain Tumors is recruiting below its size-band peers.

    1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Brain Tumors trials is spread across many organizations.

    Methodist Healthcare accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Brain Tumors enrolment sits around 119 participants.

    Median target enrolment is 119 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.

  4. Brain Tumors splits between interventional and observational designs.

    6 interventional and 5 observational studies make up this index (54.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Open and recent trials

11 total, page 1 of 1

RECRUITING 4,000 participants

Florida Center for Brain Tumor Research

University of Florida

NCT00811148

ACTIVE NOT RECRUITING 57,816 participants

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

Children's Oncology Group

NCT01117168

ACTIVE NOT RECRUITING 600 participants

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

Massachusetts General Hospital

NCT01115777

ACTIVE NOT RECRUITING Phase 1 540 participants

ALA-induced PpIX Fluorescence During Brain Tumor Resection

David W. Roberts

NCT02191488

ACTIVE NOT RECRUITING 125 participants

Blood Flow MRI for Monitoring Brain Tumors

Beth Israel Deaconess Medical Center

NCT01538264

COMPLETED NA 119 participants

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

Baylor College of Medicine

NCT00042367

COMPLETED 105 participants

Brain Tumor Treatment Satisfaction Survey

Methodist Healthcare

NCT00557375

COMPLETED Phase 2 60 participants

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

Duke University

NCT00301873

COMPLETED Phase 1 40 participants

Nicardipine vs Esmolol Craniotomy Emergence

Northwestern University

NCT01951950

COMPLETED Phase 1 15 participants

[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors

University of Utah

NCT00707343

COMPLETED Phase 1 9 participants

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

National Cancer Institute (NCI)

NCT01259479

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Named interventions

Most-linked intervention names on Brain Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

IV Zometa Drug
1 trials
Esmolol Drug
1 trials
FLT-PET Imaging Radiation
1 trials
Satraplatin Drug
1 trials
Intrathecal Mafosfamide Drug
1 trials
Regimen 1, Course 2 Drug
1 trials
Cycle B Drug
1 trials
Regimen 1, Course 1, Cycle A2 (Days 22 - 42) Drug
1 trials

US sites by state

Facility locations filed on Brain Tumors trials. A trial with sites in several states counts in each.

Tennessee 2 trials
North Carolina 2 trials
Massachusetts 2 trials
Utah 1 trials
Texas 1 trials
New Hampshire 1 trials
Maryland 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Brain Tumors page

11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Tumors condition card totals 11 registered trials; most-linked intervention IV Zometa; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.